FDA approves Lupin’s generic potassium chloride oral solution
Lupin has received Food and Drug Administration's clearance for its potassium chloride oral solution, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%).
The product is the generic version of Genus’ potassium chloride oral solution, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%). It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.
The product had a market value of approximately $184.95 million, according to June 2018 IQVIA data.
The product is the generic version of Genus’ potassium chloride oral solution, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%). It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.
The product had a market value of approximately $184.95 million, according to June 2018 IQVIA data.